MedTrace Logo

Efficacy of Changing to TRAVATAN® From Prior Therapy

NCT01510145 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2014-06-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.

Conditions

Interventions

DRUG

Travoprost 0.004% BAK-free

Containing Polyquad (PQ) preservative

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Adriana S. Bonadia · Alcon Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01510145 on ClinicalTrials.gov